UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer pain management in China: current status and practice implications based on the ACHEON survey

Journal of pain research, 2017-01, Vol.10, p.1943-1952

Xia, Zhongjun

2017

Volltextzugriff (PDF)

Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

Molecular cancer, 2022-09, Vol.21 (1), p.1-182, Article 182

2022

Volltextzugriff (PDF)

Research on data-driven multi-sensory design path based on Chinese gardens under the perspective of AI big data

Applied mathematics and nonlinear sciences, 2024-01, Vol.9 (1)

2024

Volltextzugriff (PDF)

Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations

Haematologica (Roma), 2024-02, Vol.109 (2), p.479

2024

Volltextzugriff (PDF)

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

EMBO molecular medicine, 2022-01, Vol.14 (1), p.e14502-n/a

2022

Volltextzugriff (PDF)

Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2402102

2024

Volltextzugriff (PDF)

Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo

Molecular cancer therapeutics, 2016-08, Vol.15 (8), p.1845-1858

2016

Volltextzugriff (PDF)

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

BMC medicine, 2022-04, Vol.20 (1), p.108-108, Article 108

2022

Volltextzugriff (PDF)

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China

International journal of hematology, 2021-03, Vol.113 (3), p.422-429

2021

Volltextzugriff (PDF)

Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China

Frontiers in oncology, 2022-03, Vol.12, p.772015-772015

2022

Volltextzugriff (PDF)

Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study

International journal of hematology, 2019-10, Vol.110 (4), p.458-465

2019

Volltextzugriff (PDF)

Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma

Annals of hematology, 2022-04, Vol.101 (4), p.763-771

2022

Volltextzugriff (PDF)

Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma

Blood science, 2023-10, Vol.5 (4), p.249-257

2023

Volltextzugriff (PDF)

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

Cancer biology & medicine, 2023-01, Vol.20 (1), p.77-87

2023

Volltextzugriff (PDF)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

Translational oncology, 2018-06, Vol.11 (3), p.779-785

2018

Volltextzugriff (PDF)

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma

Cancer medicine (Malden, MA), 2024-06, Vol.13 (11), p.e7347-n/a

2024

Volltextzugriff (PDF)

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy

PloS one, 2016-10, Vol.11 (10), p.e0164210-e0164210

2016

Volltextzugriff (PDF)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4134-4145

2022

Volltextzugriff (PDF)

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience

Cancer Research and Treatment, 2020, 52(2), , pp.573-585

2020

Volltextzugriff (PDF)

Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2

Journal of cancer research and therapeutics, 2023-12, Vol.19 (6), p.1495-1500

2023

Volltextzugriff (PDF)

P925: PHASE 1 TRIAL OF ANTI‐CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e1267740-n/a

2023

Volltextzugriff (PDF)

A Preliminary Study of Culture Shock and Adaptation Tactics for Overseas Chinese Students —from the Perspective of "American Dreams in China"

Theory and practice in language studies, 2020-03, Vol.10 (3), p.336-341

Xia, Zhongjun

2020

Volltextzugriff (PDF)

Monitoring the Sign & Symptoms of Variant Creutzfeldt-Jakob Disease Among Patients with Multiple Myeloma Treated with Ixazomib Capsules in China: A Real-World Pharmacovigilance Survey

Blood, 2023-11, Vol.142 (Supplement 1), p.6629-6629

2023

Volltextzugriff (PDF)

Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors

BMC cancer, 2010-07, Vol.10 (1), p.358-358, Article 358

2010

Volltextzugriff (PDF)

Real-World Outcome of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter Propensity Score Matched Case Series Study

Blood, 2022-11, Vol.140 (Supplement 1), p.12589-12590

2022

Volltextzugriff (PDF)

1 – 25 von 197

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(180)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Cancer pain management in China: current status and practice implications based on the ACHEON survey

Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming

Research on data-driven multi-sensory design path based on Chinese gardens under the perspective of AI big data

Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma

Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China

Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China

Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study

Efficacy and safety comparison between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma

Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience

Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2

P925: PHASE 1 TRIAL OF ANTI‐CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA

A Preliminary Study of Culture Shock and Adaptation Tactics for Overseas Chinese Students —from the Perspective of "American Dreams in China"

Monitoring the Sign & Symptoms of Variant Creutzfeldt-Jakob Disease Among Patients with Multiple Myeloma Treated with Ixazomib Capsules in China: A Real-World Pharmacovigilance Survey

Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors

Real-World Outcome of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter Propensity Score Matched Case Series Study

Suchergebnisse filtern